ESG Report (Chinese edition)

Overview

The report covers the fiscal year 2024, marking the company's first sustainability publication. Hexun Biosciences focuses on regenerative medicine, specifically umbilical cord-derived mesenchymal stem cell therapies and CDMO services. Key highlights include achieving a 339.62% growth in net profit and successfully registering on the emerging stock market. The company conducted its first greenhouse gas inventory for Scope 1 and 2 emissions and established a Sustainability Promotion Task Force. It also emphasizes product safety through GTP-certified facilities and maintains a strong focus on employee welfare, professional development, and occupational health and safety.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: Chinese
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment

Assurance

Provider

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview